Profil
Randall K.
Johnson worked as an Independent Director at Callisto Pharmaceuticals, Inc. from 2005 to 2013.
Prior to that, he was the Group Director of the Oncology Research Department at GSK Plc from 1982 to 2002.
He also held the same position at Smithkline Beecham Pharmaceuticals (Canada).
Anciens postes connus de Randall K. Johnson
| Sociétés | Poste | Fin |
|---|---|---|
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 22/01/2013 |
| GSK PLC | Corporate Officer/Principal | 01/02/2002 |
| Smithkline Beecham Pharmaceuticals (Canada) | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Health Technology |
| Smithkline Beecham Pharmaceuticals (Canada) |
